MLL-rearranged leukaemic cells are dependent on the serine/threonine kinase glycogen synthase kinase-3 (GSK3), prompting the investigation of GSK3 inhibitors as potential therapies in paediatric AML [39]. The gene discussed is MARK2; the disease is acute myeloid leukemia.